Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)

Sarah Dyball, Sophie Collinson, Emily Sutton, Eoghan M McCarthy, Ian N Bruce, Ben Parker

ABSTRACT

Objective To quantify how well phase III randomised clinical trials in both SLE and lupus nephritis (LN) represents a real-world SLE cohort.

Methods Literature reviews were performed of major published phase III SLE (n=12) and LN (n=6) clinical trials (ClinicalTrials.gov). Inclusion and exclusion criteria common across these trials were collated for non-renal SLE or LN trials, and applied to patients recruited to the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR) starting either biological or standard-of-care (SOC) therapies.

Results We recruited 837 patients to the BILAG-BR from September 2010 to June 2018, starting either SOC (n=125, 15%) or a biological medication (n=712, 85%). Active LN, defined as a BILAG A in the renal domain occurred in 20% (n=166). Overall, 530 (63%) patients were ineligible to participate in non-renal SLE clinical trials and 72 (43%) patients with active LN would be ineligible for LN trials. The most common reasons for ineligibility from the non-renal lupus trials included active renal involvement (n=166, 20%) and low disease activity (n=114, 15%). For LN trials, the most common exclusion met was pre-existing renal impairment (n=15, 9%). Patients with fewer comorbidities were more likely to be eligible to participate in non-renal SLE trials.

Conclusions In this national register of patients with moderate-to-severe SLE, nearly two-thirds would not be eligible for recruitment to key SLE clinical trials nor would almost half of those with active LN. Eligibility criteria may excessively constrain enrolment and thus, how we can generalise trial results in a real-world setting.

BACKGROUND

SLE is a chronic multisystem autoimmune disorder which has diverse manifestations that can range from a mild rash or arthritis to severe organ-threatening disease. LN is a severe complication of SLE and a major cause of overall morbidity and mortality with up to 30% of patients with LN progressing to end-stage renal failure.1–3

Conventional immunosuppressant medications and corticosteroids represent the standard of care (SOC) in SLE management, however, they can be associated with a range of adverse effects and are not always effective. Despite a recent series of successful trials in SLE including belimumab (BLISS-LN, BLISS-52, BLISS-76), anifrolumab (TULIP 2) and vorisporin (AURORA), a major challenge in caring for patients with SLE is the paucity of approved medications with several randomised controlled trials (RCTs) proving unsuccessful in achieving their primary end points in SLE including epratuzumab (EMBODY1/2), tabalumab (ILLUMINATE 1/2) and anifrolumab (TULIP 1).4–12

RCTs represent the gold standard to determine initial efficacy and safety of medicines,
using idealised and controlled circumstances; real-world registry data provide additional data on long-term follow-up in a broader population. Trials that focus on LN have the advantage of objective hard end points, such as protein-creatinine ratios and serum creatinine concentrations, whereas non-renal SLE trials have no clear biomarker of treatment response and as such are dependent on more subjective outcome measures such as composite indices of disease activity (eg, SLE Disease Activity Index, SLE Responder Index-4, etc). By convention, SLE clinical trials are usually divided into renal (LN) and non-renal trials.

There are complex reasons why clinical trials fail to meet their primary end points in SLE.\textsuperscript{13} Stringent inclusion and exclusion criteria are often applied to create a more homogenous disease group such as antibody positivity, involvement of specific organ systems, mandating a severity level of disease activity and use of SLE classification criteria to define the disease population. Effective SOC therapies including high-dose corticosteroids and concomitant prescribing of immunosuppressive therapies may also confuse the interpretation of trial results. Other common exclusion criteria in clinical trials include organ dysfunction or comorbidities as there may be concern that these may be incorrectly attributed to the trial medication. This may however, reduce the external validity of a clinical trial, rendering them less applicable to the intended patient population. Our aim was to quantify how accurately phase III blinded RCTs in both SLE and LN represent a real-world SLE cohort of patients with moderate-to-severe disease.

METHODS

Identification of eligible clinical studies

We searched on the ‘ClinicalTrials.gov’ database which records privately and publicly funded clinical studies conducted around the world in August 2020, first using the search term “SLE” or “systemic lupus erythematosus” and second “lupus nephritis” to identify relevant studies. In the search, we included phase III, double-blinded, RCTs involving patients with SLE, who were treated by either a biological therapy or a targeted synthetic disease-modifying antirheumatic drug. The study must have completed recruitment; however, results did not have to be formally published. We excluded trials that published data on extended follow-up of previously published RCTs, open-label studies or studies not deemed to be the principle study, such as those using an alternative method of administration or different study population in a previously trialled medication.

Patients and study design

The British Isles Lupus Assessment Group-Biologics Register (BILAG-BR) is a national, multicentre, prospective cohort study. It recruits patients with a diagnosis of SLE that are ≥5 years old and can provide informed consent. There are two arms to the BILAG-BR, a biologics cohort who are commencing or restarting biological therapy, and a SOC cohort who are newly receiving an immunosuppressant medication (including mycophenolate, azathioprine, ciclosporin, cyclophosphamide or tacrolimus) and are biologically naïve. Patients accessing a biological therapy for SLE in the UK are required to meet strict eligibility guidelines, based either on high disease activity (eg, 1 BILAG A, 2×BILAG B, SLE Disease Activity Index (SLEDAI) >6) or the need for unacceptably high doses of steroids despite optimal SOC.

Patients starting either a biological or SOC therapy were included in this cross-sectional analysis at cohort entry. Demographic details including age, disease duration, sex and race/ethnicity were noted, along with baseline laboratory results, past and current therapies and disease activity. SLE disease activity was measured by the BILAG-2004 index and SLEDAI 2000 (SLEDAI-2K).\textsuperscript{14,15} Data were collected on common comorbidities for all patients at registration in the BILAG-BR.

Non-renal lupus inclusion and exclusion criteria

We applied available data to common inclusion criteria including age ≥18 years, positive for American College of Rheumatology (ACR)-1997 SLE classification criteria,\textsuperscript{16} positive serology anti-double stranded DNA (dsDNA) or ANA antibodies (in trials these are performed in a central laboratory, for this study we recorded the antibody status at entry or within 6 months of study enrolment), and moderate-to-severe active disease, defined as a BILAG A in 1 domain or a BILAG B in ≥2 domains, or a SLEDAI-2K≥6.

Exclusion criteria common across multiple clinical trials included steroids equivalent to >40 mg prednisolone daily, active renal or neurological lupus (defined as a BILAG A in either domain) and a urinary protein-creatinine ratio (uPCR) ≥100 mg/mmol, a history of viral hepatitis B or C, a history of malignancy (excluding basal cell carcinoma), cyclophosphamide within 90 days, B-cell therapy within the previous year, CKD stage 4 or 5 and low blood counts (defined as neutrophils <1.0×10\(^9\)/L, platelets <10×10\(^9\)/L or Hb <70 g/L).

LN inclusion and exclusion criteria

Active LN was defined as a BILAG score A in the renal domain. The inclusion criteria common across majority of LN trials included age ≥18 years, meeting ACR-1997 SLE classification criteria, positive anti-dsDNA or ANA antibodies (see above) and proteinuria (defined as a uPCR >100 mg/mmol).

Common exclusion criteria in renal trials included active neurological lupus (defined as a BILAG A central nervous system (CNS) domain), a history of viral hepatitis B or C, a history of malignancy (excluding basal cell carcinoma), cyclophosphamide within 90 days, B-cell therapy within the previous year, chronic kidney disease (CKD) stage 5 and low blood counts (defined as neutrophils <1.0×10\(^9\)/L, platelets <10×10\(^9\)/L or Hb <70 g/L).
Data analysis

From the results of the literature review, common inclusion and exclusion criteria were collated from first non-renal SLE and second LN trials to create hypothetical generalised inclusion and exclusion criteria. These criteria were then applied separately to the BILAG-BR, with patients required to meet all inclusion criteria and none of the exclusion criteria to be eligible for recruitment.

Data were entered into a secure database at the University of Manchester. Baseline demographic data are presented using descriptive statistics performed using Stata V.13 (StataCorp, College Station, Texas, USA). Differences between groups were analysed using Mann-Whitney U test for continuous data or \( \chi^2 \) test for categorical data. A logistic regression model was used to test the age-adjusted and sex-adjusted association between trial eligibility and comorbidities.

RESULTS

Characteristics of RCTs included in analysis

The systematic literature review identified 634 trials in non-renal SLE and 156 in LN; of these, 571 and 140 were excluded at abstract screening, and 51 and 10 at full-text screening, respectively. The study selection process as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines is shown in online supplemental figure 1, with our final analysis including 12 studies in non-renal SLE and 6 in LN.

Inclusion criteria from non-renal SLE clinical trials

We included the following 8 investigational medicinal products over 12 non-renal SLE clinical trials (table 1). All trials required patients to meet the ACR-1997 SLE classification criteria and required positive immunology. All included trials specified a lower age limit, usually 18 years. Disease activity for inclusion was identified by BILAG in older clinical trials, requiring \( \geq 2 \) BILAG-B, SLEDAI-2K of at least 6 points, whereas the more contemporary clinical trials required a SELENA-SLEDAI score of at least 6 points. The majority of trials excluded participants taking prohibited medications including high-dose steroids (40 mg oral prednisolone or equivalent most frequently), recent cyclophosphamide or rituximab therapy. Three-quarters of all studies excluded severe active renal or CNS involvement and half the trials required a cut-off for proteinuria. Comorbidities were excluded in the majority of trials, either at the investigators discretion or severe previous or intercurrent illnesses, particularly those requiring steroids for treatment, chronic infections or previous cancer.

Inclusion criteria from LN clinical trials

There were six LN RCTs included from the literature review, as shown in table 2. The LUNAR, BLISS-LN and abetimus trials all required patients to meet the ACR-1997 SLE classification criteria and be antibody positive for ANA or anti dsDNA. LN disease activity was usually specified as class III or class IV LN within 6 months to 2 years and proteinuria, most commonly with a uPCR of 100 mg/mmol. The majority of trials required participants to be adults. Prohibited medications most frequently included previous B cell therapy, cyclophosphamide within 3 months and corticosteroid use over a given threshold.

Baseline demographics of patients in BILAG-BR

From September 2010 to June 2018, 837 patients were recruited to the BILAG-BR; 125 in the SOC cohort and 712 in the biologics cohort. The most commonly used SOC medications included mycophenolate (n=64), azathioprine (n=27) and cyclophosphamide (n=24). Rituximab was the most common biological therapy (n=662), followed by belimumab (n=47). The baseline demographics of patients in the BILAG-BR are shown in the online supplemental table 1. There were 573 (68%) patients taking oral glucocorticoids and 701 (87%) taking ≥2 BILAG-B, SLEDAI-2K of at least 6 points, whereas the more contemporary clinical trials required a SELENA-SLEDAI score of at least 6 points. The majority of trials excluded participants taking prohibited medications including high-dose steroids (40 mg oral prednisolone or equivalent most frequently), recent cyclophosphamide or rituximab therapy. Three-quarters of all studies excluded severe active renal or CNS involvement and half the trials required a cut-off for proteinuria. Comorbidities were excluded in the majority of trials, either at the investigators discretion or severe previous or intercurrent illnesses, particularly those requiring steroids for treatment, chronic infections or previous cancer.

Table 1 Included randomised clinical trials in non-renal SLE from results of literature review

| NCT ID          | Collaborator     | N    | Phase | Completion date | Trial name   | Investigational treatment |
|-----------------|------------------|------|-------|-----------------|--------------|---------------------------|
| NCT00137969     | Genentech        | 262  | II/III| 2008            | EXPLORER     | Rituximab                 |
| NCT00424476     | GlaxoSmithKline  | 865  | III   | 2010            | BLISS-52     | Belimumab                 |
| NCT00410384     | GlaxoSmithKline  | 819  | III   | 2010            | BLISS-76     | Belimumab                 |
| NCT01196091     | Eli Lilly        | 1164 | III   | 2015            | ILLUMINATE 1 | Tabalumab                 |
| NCT01205438     | Eli Lilly        | 1124 | III   | 2015            | ILLUMINATE 2 | Tabalumab                 |
| NCT01262365     | UCB              | 793  | III   | 2015            | EMBODY 1     | Epratuzumab               |
| NCT01261793     | UCB              | 791  | III   | 2015            | EMBODY 2     | Epratuzumab               |
| NCT02446912     | AstraZeneca      | 460  | III   | 2018            | TULIP 1      | Anifrolumab               |
| NCT02446899     | AstraZeneca      | 373  | III   | 2018            | TULIP 2      | Anifrolumab               |
| NCT02504645     | ImmuPharma       | 202  | III   | 2018            | LUPUZOR      | IPP-201101                |
| NCT01395745     | Anthera          | 442  | III   | 2016            | CHABLIS SC1  | Blisibimod                |
| NCT00624338     | Merck            | 461  | II/III| 2012            | APRIL/SLE    | Atacicept                 |

N, number of participants; NCT, National Clinical Trial number; UCB, Union Chimique Belge.
antimalarials. The median daily dose of oral prednisolone was 10 mg (IQR 7.5–20 mg). Hypertension (24%, n=201) was the most common comorbidity followed by depression (20%, n=167), CKD (n=100, 12%) and thyroid dysfunction (n=86, 10%). Fifty-eight per cent of patients (n=487) had one or more comorbidities.

Hypothetical inclusion and exclusion from RCTs

Overall, 307 (37%) patients with moderate-to-severe lupus would be eligible to participate in non-renal RCTs (figure 1A), 49 (39%) patients in the SOC cohort and 258 (36%) patients in the biologics cohort. There were 166 patients with a BILAG-A in the renal domain who were designated as our ‘active LN cohort’. Of these, 94 (57%) would be eligible to participate in LN trials (figure 1B), including 81 (59%) in the biologics group, and 13 (46%) in the SOC group. The number of patients meeting each individual inclusion and exclusion criteria is shown in table 3 for non-renal lupus and table 4 for LN, the completeness of data is demonstrated in the online supplemental tables 2 and 3.

Non-renal SLE cohort

A total of 593 patients met all inclusion criteria, 511 (72%) in the biologics group and 82 (66%) in the SOC group. Fewer patients in the SOC cohort had active disease (76%), defined as a BILAG A in 1 domain or a BILAG B in ≥2 domains, or a SLEDAI-2K≥6, compared with the biologics cohort (87%). The most common reason for not meeting inclusion criteria was low disease activity of SLE (n=114, 15%) and not meeting the ACR-1997 SLE classification criteria for SLE (n=71, 9%). There were 481 (86%) patients in the biologics cohort and 65 (52%) in the SOC cohort that had a BILAG A or 2 BILAG B domains present; and 476 (72%) in the biologics cohort and 72 (62%) patients had a SLEDAI-2K score of 6 or

Table 2 Included randomised clinical trials in lupus nephritis from results of literature review

| NCT ID         | Collaborator               | N     | Phase | Completion date | Trial name | Investigational treatment |
|----------------|----------------------------|-------|-------|-----------------|------------|----------------------------|
| NCT00282347    | Genentech                  | 144   | III   | 2013            | LUNAR      | Rituximab                  |
| NCT01714817    | Bristol-Myers Squibb       | 695   | III   | 2018            | ALLURE     | Abatacept                  |
| NCT03021499    | Aurinia                    | 358   | III   | 2019            | AURORA     | Vocolsporin                |
| NCT01639339    | GlaxoSmithKline            | 448   | III   | 2020            | BLISS-LN   | Belimumab                  |
| NCT00035308    | La Jolla                   | 330   | III   | 2002            |            | Abetimus                   |
| NCT00626197    | Roche Pharma AG            | 381   | III   | 2013            | BELONG LN  | Ocrelizumab                |

N, number of participants; NCT, National Clinical Trial number.

Table 3 Patients in the BILAG-BR (n=837) who did not meet the inclusion criteria or met the exclusion criteria from non-renal lupus randomised controlled trials

| Biologics (n=712) | SOC (n=125) | P value |
|-------------------|-------------|---------|
| Inclusion criteria |             |         |
| Age <18 years, n (%) | 6           | 3       | 0.127   |
| Does not meet ACR-1997 SLE classification criteria | 59 | 12 | 0.723 |
| Negative serology | 43          | 5       | 0.323   |
| Low disease activity | 86          | 28      | 0.002   |
| Exclusion criteria |             |         |
| Steroids >40 mg prednisolone daily | 9   | 8  | >0.001  |
| Active CNS lupus | 39          | 7       | 0.992   |
| Active renal lupus | 138         | 28      | 0.180   |
| Previous viral hepatitis | 20          | 1       | 0.166   |
| Previous malignancy | 51          | 5       | 0.192   |
| Cyclophosphamide <90 days before entry | 37 | 0 | 0.009 |
| B cell therapy <1 year before entry | 50 | 0 | 0.002 |
| CKD stage 4/5 | 27          | 5       | 0.789   |
| uPCR >100 mg/mmol | 92          | 20      | 0.986   |
| Low blood counts | 25          | 1       | 0.098   |
| Pregnancy | 3           | 1       | 0.571   |

ACR, American College of Rheumatology; BILAG-BR, British Isles Lupus Assessment Group-Biologics Register; CKD, chronic kidney disease; CNS, central nervous system; N, number of participants; SOC, standard of care; uPCR, urine protein-creatinine ratio.
The renal SLE trial exclusion criteria disqualified 39 (28%) patients in the biologics group and 10 (36%) patients in the SOC group. Of those who met all inclusion criteria, there were 10 (8%) patients who met two or more exclusion criteria. The most commonly fulfilled exclusion criteria were existing renal impairment (n=22, 14%), high background steroid use (n=9, 6%), history of malignancy (n=9, 5%) and prior cyclophosphamide use (n=8, 5%). The percentage of patients whose steroid dose was over 40 mg equivalent per day was higher in the SOC group compared with the biologics group. Ineligible patients did not differ from eligible patients according to disease duration (p=0.1), age (p=0.3), sex (p=0.2) or ethnicity (p=0.1).

**Comorbidities between non-renal and renal groups**

The active renal disease cohort (BILAG renal A, n=166) had higher incidence rates of hypertension (34% vs 22%, p=0.001) and pre-existing CKD stage 4 or 5 (14% vs 2%, p<0.001) compared with those who did not have active renal disease (no BILAG renal A, n=671).

**Comorbidities in patients included or excluded from clinical trials**

There were a lower number of comorbidities in patients eligible for recruitment to both types of trials. In patients with non-renal SLE, 51% (n=158/307) of eligible patients had one or more comorbidity, compared with 62% (n=329/530) of ineligible subjects. Three or more comorbidities were present in 14.2% (n=75) of patients ineligible, compared with 9.4% (n=29) of those eligible to participate. The number of patients with ≥1 comorbidity was similar in the LN cohort between those eligible and ineligible (62% vs 61%). In an age-adjusted and sex-adjusted analysis, eligibility for trial inclusion was associated with fewer comorbidities (non-renal: OR 0.71, 95% CI 0.56 to 0.88).

**DISCUSSION**

Despite unprecedented drug development in SLE in recent years, the standard of care remains limited, with a number of medications given off-label without supporting evidence from large double-blinded RCTs. Just two drugs, belimumab (SLE and LN) and voclosporin (LN only), have been approved in over 50 years, however, these are not effective in all patients with SLE and do not consistently induce full disease remission in the majority of patients.9 12 In recent years, success has been seen with both phase II and phase III trials including anifrolumab (TULIP2) in non-renal SLE.7–9 17–20 RCTs represent the most scientifically rigorous method of hypothesis testing available and are considered the gold standard for evaluating the effectiveness of interventions. Clinical trials show what can be accomplished under controlled, restricted and carefully observed conditions; however, this will not necessarily be observed when a medicine is authorised for general use.
This study is the first to compare a large national registry of patients with SLE with moderate-to-severe disease, the BILAG-BR, to major published eligibility criteria from RCTs in non-renal SLE and LN. We have shown that 63% of patients with non-renal SLE and 43% of patients with LN would not be eligible to participate in an RCT. These results indicate that phase III clinical trials results may only partially reflect real-world SLE cohorts with similar levels of disease activity. When interpreting the results of clinical trials, caution should be paid in reviewing whether all patients have been adequately represented in the clinical trial.

Patient safety must be paramount in clinical trials. This study uses inclusion and exclusion criteria from phase III trials which focus on proving efficacy for licencing, and confirming the safety profile from phase II trials in a broader population. Clinical trials are notoriously difficult to recruit due to the low abundance of participants in the outpatient lupus population. This study highlights the ability to improve clinical trial recruitment through the aggregation of marginal gains. There is wide variation in acceptable exclusion criteria (and individual thresholds of each, eg, estimated glomerular filtration rate, time from previous anti-CD20 therapy, etc). Therefore, each criterion needs to be critically reviewed to ensure it is safeguarding participants’ safety, and not at the expense of reducing recruitment potential and thus the external validity of the trial. This must be done with careful reference to the mechanism of action of the investigational drug.

This analysis reported no significant difference in the ethnicity of UK patients eligible for RCTs based on common published inclusion and exclusion criteria. Previous studies have reported that real-world participation in SLE clinical trials does vary by ethnicity, suggesting external factors responsible for the lack of representation of ethnic minorities in clinical research. These may include both patient barriers (such as language) to participation and clinician barriers in referring patients for consideration

the Lupus Foundation of America is presently undertaking work with the aim of increasing awareness of SLE research in under-represented populations and the ACR’s lupus initiative is dedicated to reducing health inequalities among disproportionately affected populations. This is important as low participation in SLE RCTs from ethnic minority groups results in a lack of data on the effectiveness and safety of treatments in those who have the highest morbidity and mortality from SLE. More diverse recruitment strategies, with an emphasis on hard-to-reach populations, will lead to better generalisability of results.

Our literature review showed that non-renal SLE and the majority of LN trials required patients to be defined using the ACR-1997 SLE classification criteria and be seropositive for an autoantibody at the time of recruitment. Classification criteria are used in clinical trials to identify a well-defined population of patients with high specificity for SLE, however, they are not diagnostic criteria and may exclude a significant proportion of patients. In both renal and non-renal trials, recent seropositivity was frequently required for inclusion, which would result in 6% of patients in BILAG-BR being excluded from clinical trials. A secondary analysis of the phase II belimumab trial had noted greater efficacy for belimumab in patients with SLE with a positive ANA or anti-dsDNA antibody at trial entry. The phase III BLISS trial programme carried forward this entry criteria which is now standard across most other SLE trials with these tests routinely tested centrally prior to recruitment to clinical trials. Whether active serology at trial entry is necessary for all SLE trials, or only for B-cell targeted therapy remains to be demonstrated. If these criteria were removed more patents in our cohorts would theoretically be eligible.

Clinical trial recruitment is challenging due to the low abundance of patients in the outpatient lupus population. In the years 2018–2020, recruitment to BILAG- BR from over 60 UK centres was on average 16 patients per month. Results from this analysis show that only 37% of patients with moderate-to-severe SLE would be eligible for recruitment to non-renal clinical trials. Across the UK, this would translate to six patients per month being eligible for clinical trials. There is therefore a limit to the number of lupus trials that potentially could be open in a country such as the UK at any given time. To date, 62 centres have contributed to the BILAG- BR, however, the top 10 recruiting centres account for 67% (962/1435) of all patients recruited. It is important that patients with active lupus are managed in collaboration with a large centre so that patients can be recruited to clinical trials.

Currently, there are many trials recruiting globally, with eight RCTs (including six phase II and two phase III) in SLE actively recruiting in the UK (Clinical Trials.gov; December 2020). As every individual inclusion and exclusion criteria impacts patient recruitment, careful scrutiny is needed before adoption. Our data suggest that exclusion criteria should be minimised where safe to do so, and phase III protocols should be ‘forgiving’ to maximise recruitment potential and speed their conduct.

Certain SLE disease manifestations are excluded in trials to improve patient safety, such as CNS involvement in SLE which has high morbidity. We found that 46 (6%) patients would be excluded due to active CNS SLE. As RCTs exclude these patients, there is no high-quality evidence for their management, and dedicated trials in CNS lupus are needed.

This study showed that in non-renal clinical trials, patients excluded from participating in clinical trials had a cumulatively larger mean number of comorbidities than those included. Similar studies have been carried out in the field of oncology with chemotherapy trials being more likely to exclude patients with severe disease such as CNS metastasis, comorbidities and history of other malignancies. Despite this, excluding the patients who may be more likely to represent the population treated in clinical settings leaves patients susceptible to unintended harm from inappropriate generalisation of trial results. One
solution may be to have less stringent limits on comorbidities at recruitment where safe to do so, with stratification of recruitment groups based on comorbidities. We would advocate a focused approach to this, with careful scrutiny of the mechanism of action of the experimental drug. For example, allowing levels of CKD in therapies with no known renal toxicity concerns.

An additional challenge for drug development is that patients with SLE are treated with corticosteroids and other immunosuppressive medications, which cannot be discontinued on joining an RCT. This increases the placebo response rate in trials, which can obscure the effects of trial medications, particularly if they are only moderately efficacious. Most studies excluded patients that had received rituximab within a year or cyclophosphamide in the previous 6 months due to their long-lasting effects. This results in patients’ refractoriness to medications being excluded from clinical trials and potentially altering treatment, further reducing the trial population. Suggested mitigations of this include measurement of B-cell reconstitution prior to enrolment. There is also wide variation in corticosteroid dosing by clinicians, some of which is driven by patient-independent factors.30 We would suggest a focus in the early phase of the trial to allow a protocol-led harmonisation and standardisation of steroid dosing.

This study does have limitations. Complete data were not available for every patient in this study. We assessed the amount of people who did not meet all inclusion criteria or who met an exclusion criteria. Employing this methodology may have led to a conservative estimate of patients who would be ineligible for clinical trial participation. It is unlikely that data are ‘missing at random’ and for variables where there is a high percentage of missing data, such as uPCR, this likely represents a bias to those without an available measurement being more likely to have a normal result.

Additionally, many of the clinical trials that formed our eligibility criteria excluded patients at the discretion of the principle study investigator, such as those with ‘serious intercurrent illness’ or conditions requiring significant steroid use. It is difficult to accurately conclude which patients in BILAG-BR would be deemed ineligible on this basis. Other eligibility criteria from other trial protocols were not included in this study, such as no recent live vaccination, no recent dose adjustments in background medications and no investigational biological agents. By not being able to fully describe the nuance of eligibility criteria in clinical trials, this study is likely to underestimate the number of patients not eligible for phase III clinical trials.

A further limitation is that the SLICC 2012 criteria for SLE may be used in lieu of the ACR-1997 criteria in the classification of SLE in some clinical trials. BILAG-BR started prior to these being published, therefore data on SLICC criteria are not complete in the BILAG-BR and have not been presented.31

CONCLUSION

This is the first study to compare a national registry of patients with moderate-to-severe SLE to major published RCTs in SLE and LN. We found that nearly two-thirds of patients with moderate-to-severe non-renal SLE and almost a half of patients with active LN would not be eligible for participation in clinical trials. These results indicate that phase III clinical trial results may only partially reflect real-world SLE cohorts. When interpreting the results of these clinical trials, caution should be paid in reviewing whether the patient has been adequately represented in the clinical trial.

Twitter Sarah Dyball @sarahandybal1 and Ian N Bruce @Lupusdoc

Acknowledgements BILAG-BR collaborators—Dr Hazem Youssef, Aberdeen Royal Infirmary; Professor David Jayne, Addenbrooke’s Hospital; Dr Liza McCann, Alder Hey Children’s Hospital; Dr Anurag Bharadwaj, Basildon Hospital; Dr Ed Vital, Chapel Allerton Hospital; Professor Caroline Gordon, City Hospital Birmingham, Sandwell and West Birmingham Hospitals NHS Trust; Dr Deepi Kapur, Countess of Chester Hospital; Professor Chee-Seng Yee, Doncaster Royal Infirmary; Dr Bridget Griffiths, Freeman Hospital Newcastle; Dr Laila Al Swedian, George Eliot Hospital NHS Trust; Dr David D’Cruz, Guy’s Hospital; Dr Asad Zoma, Hairmyres Hospital; Dr Erin Vermaak, Haywood Hospital; Dr Francesco Carlucci, Imperial College Hospital; Dr Richard Watts, Ipswich Hospital; Dr Patrick Gordon, King’s College Hospital; Dr Shireen Shaffu, Leicester Royal Infirmary; Dr Jananath Wijeyekoon, Lister Hospital; Dr Zoe McLaren, Liverpool University Hospitals NHS Foundation Trust; Dr Mike Batley, Maidstone Hospital; Dr Luke Gompels, Musgrove Park Hospital; Dr T Sheeran, New Cross Hospital and Cannock Chase Hospital; Dr Chetan Mukhtar, Norfolk and Norwich University Hospital; Dr Rachel Jeffery, Northampton General Hospital; Dr Shahir Hamdulay, Northwick Park Hospital; Dr Fouz Rahmeh, Poole Hospital NHS Foundation Trust; Dr Steven Young Min, Queen Alexandra Hospital Portsmouth; Dr Ben Rhodes, Queen Elizabeth Hospital Birmingham; Dr Denise De Lord, Queen Elizabeth the Queen Mother Hospital, Margate; Dr Peter Lanyon, Queen’s Medical Centre, Nottingham; Dr Antoni Chan, Royal Berkshire Hospital; Professor Lee-Suan, The Royal Blackburn Hospital; Dr Jonathan Marks, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust; Dr David Hutchinson, Royal Cornwall Hospital; Dr Marian Regan, Royal Derby Hospital; Dr Richard Haigh, Royal Devon and Exeter Hospital; Dr Richard Stratton, Royal Free Hospital; Dr Corrill Rhys-Dillon, Royal Glamorgan Hospital; Dr Mohamed Akil, Royal Hallamshire Hospital; Dr Devesh Mewar, Royal Liverpool and Broadgreen Hospital; Dr Sarah Skeoch, Royal United Hospitals Bath; Dr Nicola Erb Russells Hall Hospital; Dr Edmond O’Riordan, Salford Royal NHS Trust; Dr Sarah Bartram, Salisbury District Hospital; Dr Mary Gayed, Solihull Hospital; Dr Bhaskar Dasgupta, Southend Hospital NHS Trust; Dr Harsha Gunwardena, Southmead Hospital Bristol; Dr Dev Pyne, St Bartholomew’s Hospital; Dr Arvind Kaul, St George’s Hospital; Dr V E Abernethyst,Helens and Knowsley Teaching Hospitals NHS Trust; Dr Bhruig Raj Sood, St Helier Hospital; Dr Mike Batley, Tunbridge Wells Hospital; Professor David Isenberg, University College Hospital; Dr Nicola Guillick, University Hospital Coventry & Warwickshire; Professor Christopher Edwards, University Hospital Southampton; Dr Joanna C Robson, University Hospitals Bristol NHS Foundation Trust; Dr Jon King, University Hospitals Plymouth NHS Trust; Dr Adrian Farrell, Worcestershire Acute Hospitals; Dr Sahena Haque, Wythenshawe Hospital; Dr Sally Knights, Yeovil District Hospital.

Contributors SD, SC, ES, EMMcC, INB and BP contributed to the design of the study. SD and SC completed the literature review of clinical trials in SLE. SD, SC and ES have analysed the data and performed statistical analyses. All authors have discussed the results and contributed to the writing of the manuscript and approved the final manuscript.

Funding The BILAG-BR acknowledges funding from Lupus UK, Roche and GSK. SD is an MRC Clinical Training Fellow based at the University of Manchester supported by the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics, which is funded by the Medical Research Council (Award Ref. MR/N02589/1), Roche Pharma, Eli Lilly and Company Limited, UCB Pharma, Novartis, the University of Liverpool and the University of Manchester. INB is a National Institute for Health Research (NIHR) Senior Investigator and is funded by the NIHR Manchester Biomedical Research Centre, BP is supported by the NIHR Manchester Biomedical Research Centre and NIHR Manchester Clinical Research Facility.
REFERENCES

1. Cervera R, Khamsiha MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine* 2003;82:299–308.

2. Danila MI, Porn-Estel QJ, Zhang J, et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. *Rheumatology* 2009;48:542–5.

3. Mok CC, Kwok RCL, Yip PSF. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. *Arthritis Rheum* 2013;65:2154–60.

4. Arriens C, Polyakovska S, Adzerikho I, et al. OP0277 Aurora phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN). *Ann Rheum Dis* 2020;79:172.2–3.

5. Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. *Ann Rheum Dis* 2016;75:332.1–3.

6. Navarra SV, Guzman RM, Gallagher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet* 2011;377:721–31.

7. Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. *Lancet Rheumatol* 2019;1:e208–19.

8. Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in active systemic lupus erythematosus. *N Engl J Med* 2020;382:211–21.

9. Furie R, Rovin BH, Houssiau F, et al. Two-Year, randomized, controlled trial of belimumab in lupus nephritis. *N Engl J Med* 2020;383:1117–28.

10. Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with active systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. *Ann Rheum Dis* 2016;75:323–31.

11. Clowse MEB, Wallace DJ, Furie RA, et al. Efficacy and safety of Epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. *Arthritis Rheumatol* 2017;69:362–75.

12. Furie R, Petri M, Zamaní O, et al. A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum* 2011;63:3918–30.

13. Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. *Lupus Sci Med* 2017;4:e000239.

14. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004, development and initial validation of an updated version of the British Isles lupus assessment group’s disease activity index for patients with systemic lupus erythematosus. *Rheumatology* 2005;44:902–6.

15. van Vollenhoven RF, Li F. Current value of the time of study registration.

16. Clowse MEB, Wallace DJ, Furie RA, et al. Efficacy and safety of Epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. *Arthritis Rheumatol* 2017;69:362–75.

17. Wallace DJ, Furie RA, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet* 2018;392:222–31.

18. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. *Lancet* 2018;392:1330–9.

19. Arriens C, Polyakovska S, Adzerikho I, et al. OP0277 Aurora phase 3 study demonstrates Voclosporin statistical superiority over standard of care in lupus nephritis (LN). *Ann Rheum Dis* 2020;79:172.2–3.

20. Hermann V, Battal A, Smakotina S, et al. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. *Lupus Sci Med* 2019;6:e000354.

21. Falasinnu T, Chaichian Y, Bass MB, et al. The representation of gender and race/Ethnicity in clinical trials of individuals with systemic lupus erythematosus. *Curr Rheumatol Rep* 2018;20:20.

22. Sheikh SZ, Wanty NI, Stephens J, et al. The state of lupus clinical trials: minority participation needed. *J Clin Med* 2019;8:1245.

23. Korbet SM, Schwartz MM, Evans J, et al. Severe lupus nephritis: racial differences in presentation and outcome. *J Am Soc Nephrol* 2007;18:244–54.

24. Bernatsky S, Bolvin J-F, Joseph L, et al. Mortality in systemic lupus erythematosus. *Arthritis Rheum* 2006;54:2550–7.

25. Zhang F, Bae S-C, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. *Ann Rheum Dis* 2018;77:355–63.

26. Aringer M, Costenbader K, Daikh D, et al. 2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis* 2019;78:1151–9.

27. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. *Arthritis Rheum* 2012;64:2328–37.

28. Duma N, Kothadia SM, Azam TU, et al. Characterization of comorbidities limiting the recruitment of patients in early phase clinical trials. *Oncologist* 2019;24:98–102.

29. Unger JM, Hershman DL, Flerie ME, et al. Association of patient comorbidity with cancer clinical trial participation. *JAMA Oncol* 2019;5:326–33.

30. Little J, Parker B, Lunt M, et al. Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012;64:2677–86.